Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The new formulation of Trixeo Aerosphere replaces the ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

AstraZeneca's Breztri Aerosphere in India is made using a new type of gas (called a next-generation propellant) that does not contribute much to climate change.

In 2022, AstraZeneca announced a partnership with Honeywell to develop respiratory inhaled medicines with the new propellant ... Trixeo Aerosphere inhaler for COPD" was originally created and ...

Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...

When you are diagnosed with COPD, it is important to remember that you are not alone. A healthcare team, which may include a ...